Our innovative service harnesses the power of physiologically relevant patient-derived organoids to

Develop
new models

Bring patients enrolled in clinical trials into the lab by developing new organoid models

Predict patient response

Gauge the efficacy of your drug by simulating clinical trials in organoids

Stratify patient population

Prioritise participant enrollment by identifying responders and non-responders in prospective trials

Discover novel biomarkers

Delve into the underlying mechanism of response or non-response and discover novel biomarkers

Curious to know more?

PUBLICATION

Rectal Organoids Enable Personalized Treatment of Cystic Fibrosis

read now

POSTER

Explore the predictive value of PDOs in metastatic colorectal cancer patients

download now

PUBLICATION

Pancreatic cancer organoids recapitulate disease and allow personalized drug screening

read more

Get in touch

Discover the transformative potential of our technology with a free consultation with an expert
X

Have any questions?

contact us
PRESS RELEASE

Merck to Acquire HUB Organoids Holding B.V., Advancing Next Generation Biology Portfolio

learn more

Powered by